Bristol-Myers Squibb Company Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc.

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) is commencing today, through its wholly owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). Bristol-Myers Squibb announced on Friday, June 29, 2012, its intent to acquire Amylin.

Back to news